Publications by authors named "Yuriko Okuma"

Claim this Profile
I
Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors.
Taihei Ono, Satoshi Igawa, Shintaro Kurahayashi, Yuriko Okuma, Ai Sugimoto

Invest New Drugs· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of Nivolumab and Utility of Neutrophil-to-Lymphocyte Ratio as a Predictive Biomarker for Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study.
Tomoya Fukui, Yuriko Okuma, Yoshiro Nakahara, Sakiko Otani, Satoshi Igawa

Clin Lung Cancer· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Smoking History as a Predictor of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations.
Noriko Nishinarita, Satoshi Igawa, Masashi Kasajima, Seiichiro Kusuhara, Shinya Harada, Yuriko Okuma

Oncology· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive-disease small cell lung cancer in the elderly and patients with poor performance status.
Satoshi Igawa, Masayuki Shirasawa, Takahiro Ozawa, Noriko Nishinarita, Yuriko Okuma

Thorac Cancer· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
Satoshi Igawa, Masayuki Shirasawa, Tomoya Fukui, Noriko Nishinarita, Hideyuki Sone, Yuriko Okuma

Oncology· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis